Loading…
Loading…
See exactly how ITM's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ITM and 80,000+ other tickers.
The Fund seeks to replicate, before fees and expenses, the price and yield performance of the ICE Intermediate AMT-Free Broad National Municipal Transition Index. The Intermediate Index is comprised of publicly traded municipal bonds that cover the US dollar denominated intermediate term tax-exempt bond market.
ITM Power PLC (AIM:ITM) said a £46.5 million grant from the Department for Energy Security and Net Zero has been formally awarded, giving the electrolyser maker public-sector backing for its next-generation Chronos manufacturing line in Sheffield. The grant, first announced in April, comes alongside a £40 million equity investment from Great British Energy.
Garching / Munich, July 7, 2026 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the publication of its primary result analysis of the Phase 3 COMPETE trial in The Lancet. The clinical data demonstrated that non-carrier-added (n.c.a.) 177Lu-edotreotide (also known as 177Lu-edotreotide or ITM-11) significantly improved progression-free survival (PFS) compared to everolimus in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The publication, titled “[177Lu] Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial,” appeared online on July 2, 2026, and can be accessed via the following link: doi.org/10.1016/S0140-6736(26)00604-5. “COMPETE provides the first high-level evidence directly comparing peptide receptor radionuclide therapy (PRRT) with everolimus, a commonly used systemic standard-of-care therapy, in the treatment of advanced GEP-NETs,” said Jaume Capdevila, MD, PhD, last author, study investigator and senior medical oncologist at Vall d'Hebron University Hospital, Barcelona. “The efficacy and safety results observed with 177 Lu-edotreotide support its consideration as a potential treatment option for appropriate patients, including those whose disease has progressed following somatostatin analog (SSA) therapy.” “Publication of these data in a peer-reviewed journal underscores the scientific importance of the COMPETE study and provides an important forum for dissemination of the results,” added Thomas Walter, MD, PhD, first author, study investigator and professor of gastroenterology, Hospices Civil of Lyon, France. “These findings offer additional insights into PRRT and support 177Lu-edotreotide as a potential therapeutic option in advanced GEP-NETs, where a high unmet need remains.” COMPETE Trial Results The randomized, open-label Phase 3 COMPETE trial evaluated n.c.a. 177Lu-edotreotide versus everolimus in 309 patients with advanced, progressive, Grade 1 or Grade 2 SSTR-positive GEP-NETs across 49 global sites. Patients were randomized 2:1 to receive 177Lu-edotreotide every three months for up to four cycles or everolimus daily for up to 30 months. Patients were not required but permitted to receive SSAs at the investigator's discretion for symptom control only. Overall, 21% of patients received concomitant SSA treatment during the study, with similar proportions receiving SSAs in each treatment arm. Top line results of the trial were initially presented at ENETS 2025 and ESMO 2025. Key findings from the COMPETE trial include:
Muni ETFs just posted record inflows. Jim Colby on why low volatility, strong risk-adjusted returns, and tax-advantaged yields keep drawing investors in.
ITM Power PLC (AIM:ITM) and Ceres Power Holdings PLC (LSE:CWR, OTC:CPWHF) have staged two of the most dramatic recoveries on the London market this year, with their shares up 160% and 230% respectively since January. Jefferies has responded by sharply upgrading its price targets on both stocks while sounding a note of caution about valuations that are beginning to echo the hydrogen hype of 2021.
ITM Power PLC (AIM:ITM) shares soared, rising more than 35% to 127.56p, after it announced it has teamed up with Rheinmetall AG on a defence-focused synthetic fuels project that could open a repeatable route for large-scale electrolyser deployments, as the pair target a planned Europe-wide network of decentralised e-fuel plants for NATO armed forces. The collaboration centres on Rheinmetall's Giga PtX project, which is designed to strengthen defence energy resilience, sovereign fuel capability and operational readiness.